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BACKGROUND: We previously reported preliminary results of our phase I study of continuous daily sorafenib with bevacizumab every
other week for solid tumours. Toxicity was moderate, leading to additional dose levels (DL) testing intermittent sorafenib dosing.
METHODS: Seventeen patients with advanced solid tumours were treated on three additional DLs testing sorafenib days 1–5 per
week. Dose level 4 was sorafenib 200mg twice daily (b.i.d.) and bevacizumab 5mgkg
 1. DL5 alternated between bevacizumab
10mgkg
 1-sorafenib 200mg b.i.d. (A) and sorafenib 400mg b.i.d. with bevacizumab 5mgkg
 1 (B). Outcome and toxicity data from
19 epithelial ovarian cancer (EOC) patients from DL 1–5 were analysed.
RESULTS: Fewer patients required sorafenib dose reduction with the intermittent schedule (41 vs 74% daily, P¼0.01). Hand–foot skin
reaction (HFSR) remained the primary cause of dose reduction (n¼5). Partial responses (12%) or disease stabilisation X4 months
(53%; median 6 (4–26)) occurred in most patients on the intermittent schedule. Partial response occurred in 47% EOC patients
treated in pooled analysis of duration 4–37 months.
CONCLUSION: Intermittent sorafenib dosing with bevacizumab has promising clinical activity and less sorafenib dose reduction and side
effects, but does not ameliorate HFSR. We are conducting a phase II clinical trial with intermittent sorafenib and bevacizumab in
patients with EOC.
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Small-molecule signal-transduction inhibitors (STIs) with oral
bioavailability have demonstrated single-agent clinical activity in
tumours with documented molecular defects in dominant
biochemical pathways. Signalling pathway targets inhibited by
STIs include the bcr–abl fusion protein in chronic myelogenous
leukaemia, and c-kit or epidermal growth factor receptor
mutations in gastrointestinal stromal tumours and non–small-cell
lung cancer (Druker et al, 2001; Demetri et al, 2002; Lynch et al,
2004). Combination strategies using signal inhibitory agents with
related targets have the potential to induce biochemical and
clinical synergism. Signalling interactions would lead to the
expectation that therapeutic interruption of pathways in series
(vertical inhibition) may allow administration of lower doses
of agents that intersect the pathway at multiple sites (Araujo
et al, 2007).
Sorafenib is a multikinase inhibitor that targets RAF kinase,
VEGFR2, platelet-derived growth factor-a and -b, and c-KIT
(Escudier et al, 2005; Llovet et al, 2008; Azad et al, 2008b).
Sorafenib is approved for use in advanced renal cell carcinoma
(RCC) and hepatocellular carcinoma (Escudier et al, 2007; Llovet
et al, 2008). Bevacizumab, an anti-vascular endothelial growth
factor (VEGF) antibody, demonstrated single-agent activity in
relapsed epithelial ovarian cancer (EOC), with a response rate of
17% in platinum-resistant patients (Burger et al, 2007; Cannistra
et al, 2007). The addition of bevacizumab to chemotherapy has
resulted in improved survival in phase III studies in patients with
metastatic colorectal, non-small-cell lung and breast cancers
(Hurwitz et al, 2005; Sandler et al, 2006; Miller et al, 2007).
We reported preliminary results of a phase I trial of a
combination of bevacizumab and sorafenib in 39 patients with a
variety of tumour types (Azad et al, 2008a,b). Our results showed
an unexpectedly high partial response rate (PR¼46%) in patients
with relapsed EOC compared with 16–21% response rate reported
with bevacizumab alone. The regimen of daily oral sorafenib
200mg twice daily (b.i.d) and bevacizumab 5mgkg
 1 every 2
weeks was tolerable. However, 62% of patients experienced fatigue,
hand–foot skin reaction (HFSR) syndrome, hypertension, protei-
nuria, and/or thrombocytopenia necessitating dose reduction to
daily sorafenib after 2–4 months of therapy. In recognition of the
interactive toxicity, we moved to an intermittent schedule using
5 days of sorafenib each week. We now provide results of
intermittent sorafenib dosing on three dose levels (DLs) in 17
additional patients with solid tumours. We include a pooled
analysis of outcome in the 19 relapsed EOC patients treated with
bevacizumab and sorafenib in all administered DLs of the trial,
both those receiving continuous sorafenib in the first part of
the trial, as well as those receiving intermittent sorafenib in these
three DLs.
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Eligibility
This study was approved by the Institutional Review Board of the
National Cancer Institute. Written informed consent was obtained
from all patients before enrolment. Eligibility requirements were as
follows: advanced solid tumours, no treatment for at least 4 weeks,
ECOG performance status of 0 or 1, leukocyte count X3000ml
 1,
absolute neutrophil count 41200ml
 1, platelet count
X100000ml
 1, serum creatinine p1.5mg per 100ml, transami-
nases p2.5  upper limit of normal (ULN), bilirubin p1.5mg per
100ml, and normal amylase and lipase. Coagulation parameters
within 1.25  ULN and (corrected) blood pressure (BP) of p140/
90mmHg were required. Preexisting treatment-related toxicity
must have recovered to grade 1 or better. Patients with brain
metastases, cardiac arrhythmias requiring treatment, active infec-
tion, hemoptysis, recent thrombosis, or bleeding diatheses were
excluded.
Treatment plan
Three additional dose levels (DLs) incorporating b.i.d. oral S 5
days of 7 each week with every 2-week intravenous bevacizumab
were tested as described in Table 1. There was a 6-week accrual
pause between DLs to monitor for delayed toxicity. A history,
blood pressure measurement, and urine protein/creatinine ratio
were performed before each bevacizumab dose, with detailed
history and physical examination every cycle (Azad et al, 2008b). If
the urine protein/creatinine ratio was greater than 1.0 but less than
grade 3, bevacizumab was given and a 24-h urine was collected for
measurement of protein before the next cycle. Bevacizumab was
held if proteinuria exceeded 2g per 24h.
Dose-limiting toxicity and dose modifications
Dose-limiting toxicity (DLT) was defined as any recurrent grade 2
or single grade 3 or greater event related to study medications
occurring within the first 6 weeks of treatment as delimited by the
CTCAEv3 with the following exception: patients with a history of
hypertension requiring therapy were allowed one additional
antihypertensive drug, whereas up to two agents could be
introduced to previously normotensive patients. Dose levels were
expanded to six patients if a DLT was observed. Documented grade
2 or 3 toxicity required a hold in therapy until toxicity resolved to
grade 1. Patients were dose reduced by one level for grade 3
toxicity or recurrent grade 2 toxicity; treatment was discontinued
for grade 4 toxicity. Patients monitored BP at home daily for the
first 4 weeks; BP in excess of 160/100mmHg required intervention,
with stability below that level for 3 days required for additional
treatment. If two or more patients were found to have DLT, the
MTD was considered to have been exceeded.
Patient monitoring, response assessment, and statistics
Pretreatment assessments were performed within 2 weeks of
therapy initiation. Patients were seen in clinic every 2 weeks for the
first two cycles of treatment, then monthly. Reassessment imaging
was performed every 8 weeks and evaluated by the reference
radiologist without knowledge of the patient’s clinical status.
Tumour effects were characterised using RECIST v1.0 (Therasse
et al, 2000).
RESULTS
Patient accrual and dose escalation and determination of
MTD
An additional 17 patients on DL 4 and 5 A/B were accrued and
received a median of four cycles of therapy (range: 1.5–26 cycles).
Two of five patients in DL 5B took 200mg b.i.d. instead of 400mg
and were assessed as assigned (intent-to-treat). Nineteen patients
with platinum-resistant EOC who received therapy on DLs 1–5
received a median of five cycles (range 1.5–37 cycles; Table 2).
Dose-limiting toxicity was observed, defining DL 4 as the MTD
(Table 3).
Table 1 Distribution of patients: dose levels (DLs; intent-to-treat)
DL No. (n¼17)
Ovarian cancer
(n¼19)
Sorafenib
(mg b.i.d., days every week)
Bevacizumab
(mgkg
 1 every 2 weeks)
Cycles, median
(range)
1
a 10 200 D1-7 5 9.5 (2–37)
2
a 3 200 D1-7 10 4 (4–5)
4
b 7 3 200 D1-5 5 4 (2–26)
5A 5 2 200 D1-5 10 2 (2–9)
5B 5 1 400 D1-5 5 5 (2–8)
aPreviously reported DL 1 (n¼33) and DL 2 (n¼6).
bDL 3 did not enroll because of dose-limiting toxicity at DL 2.
Table 2 Patient characteristics
DL 4, 5A, 5B
(n¼17)
Ovarian cancer
(n¼19
a, all DLs)
Characteristics Value
Age, years
Median 60 52.5
Range 37–74 year old 40–61 year old
No. of patients 17 19
ECOG performance status
05 1
11 2 1 8
Sex
Female 14 19
Male 3 0
Previous anticancer treatments
All, median (range) 3 (1–7) 5 (1–11)
Chemotherapy, median (range) 2 (1–7) 4 (1–9)
b
Radiation, median (range) 1 (1–5) 0
Tumour type N¼17
Ovarian cancer 6 19
a
Uterine 3
Cervical 2
Breast 2
Melanoma 1
Sarcoma 1
Basal cell cancer 1
Urothelial cancer 1
aPlatinum resistant (n¼19), sensitive (n¼0).
bDose levels (DL) 4, 5 A/B: hormonal
therapy (n¼1), immunotherapy (n¼1). Ovarian cancer: hormonal therapy (n¼6),
immunotherapy (n¼2), targeted therapy (n¼3).
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Dose-limiting toxicity of grade 3 hypertension and transaminitis
was noted in DL 5A, and grade 3 diarrhoea, hypertension, and
transaminitis were dose limiting in DL 5B (Table 4). Previously
reported DLT was on DL 2, 200mg b.i.d. continuously with
10mgkg
 1 bevacizumab every other week, and consisted of grade
3 thrombocytopaenia and proteinuria; these were not observed in
DL 4 and 5 A/B. Additional serious adverse events on the
intermittent schedule included two patients with cervical cancer on
DL 5B who developed rectovaginal fistula (n¼1, grade 2, after
cycle 2) and appendiceal perforation (n¼1, grade 3, after 4 cycles),
respectively. Sorafenib was reduced to 200mg daily, days 1–5
of 7 after fistula repair surgery. The patient with appendiceal
perforation had sorafenib dose reduction to 400mg once daily,
days 1–5 of 7 for grade 2 HFSR and mucositis after cycle one. Both
patients were treated with radiation therapy before study and had
confirmed stable disease (SD) with this trial (7 and 5 months).
Overall, 7 of 17 (41%) patients required sorafenib reduction to
200mg once daily, days 1–5 of 7. Dose modifications of sorafenib
occurred at a median of 2 cycles for patients started on sorafenib
400mg b.i.d. (DL 5B) and at a median 3.5 cycles for patients
started on sorafenib 200mg b.i.d. Primary cause for dose reduction
was HFSR (n¼5/7). Other causes were oral mucositis (n¼2),
anorexia/fatigue/weight loss (n¼1), and fistula (n¼1). Although
the number of patients are small, we observed that fewer patients
on DL 4–5 B required sorafenib dose reduction to 200mg daily,
than patients on the continuous sorafenib dose schedule (7/
17¼41% vs 29/39¼74%). Eight of 10 patients who remained on
treatment for 4þ months required sorafenib dose reduction.
Hypertension was an expected adverse event for both agents and
we reported interactive increase in hypertension with the
continuous schedule. Grade 1–3 hypertension developed in 76%
(13 of 17) patients and required institution or modification of
an antihypertensive regimen (Table 3). The protocol defined
independent dose reduction criteria. The incidence of hyperten-
sion was similar between the two sorafenib dose schedules.
Skin rashes (14 HFSR and 2 other) were observed in 16 of 17
(94%) patients; sorafenib dose was reduced in six patients for
recurrent grade 2 rashes (HFSR¼5, ear rash¼1). Grade X2
mucositis occurred in five (29%) patients. One patient had mouth,
tongue, throat, and anal mucositis. The other patient developed ear
and perirectal desquamation and rashes. Temporary interruption
of sorafenib administration for 3–5 days or reduction to a single
dose of 200mg daily was associated with a rapid symptom
improvement. Although non-statistically significant, a trend
towards less dermatologic toxicity with intermittent S was
observed compared with original DLs (47 vs 59%).
Two study deaths occurred, one during a treatment hold and
one shortly after treatment was discontinued. One patient in DL 5A
with urothelial cancer died of progressive disease and pneumonia
after cycle one. One patient in DL 5B with endometrial cancer
developed a left leg deep vein thrombosis after cycle one, and died
at home 1 week later. Drug had been held during initiation of
anticoagulation and had not been reinstituted at the time of her
death. Neither was felt to be probably or definitely related to drug.
Clinical and tumour response
All patients enrolled into the study had progressive disease at the
time of enrolment. Partial response or SD lasting X4 months was
seen in 10 of 17 (59%) patients on intermittent sorafenib treatment
(Table 5), similar to the 59% rate observed in those receiving
continuous sorafenib on DL 1–2. No loss of clinical benefit was
thus apparent with the intermittent dosing of sorafenib.
Analysis of all EOC patients receiving sorafenib and
bevacizumab therapy
A further analysis of all EOC patients treated with bevacizumab
and either continuous or intermittent sorafenib was undertaken.
Six patients with platinum-resistant EOC were accrued in DL 4–5
B for a total of 19 patients over all DLs. The pattern of toxicity and
dose reduction was not different in the EOC patients on
continuous and intermittent sorafenib dosing. The most common
causes of dose reduction in EOC patients were HFSR (n¼8),
anorexia/fatigue/weight loss (n¼2), infection (n¼2), other rash
(n¼2), thrombocytopaenia and proteinuria (n¼1), and colon
obstruction (n¼1). Most (84%) experienced grade 1–3 hyperten-
sion. Grade 1–2 HFSR occurred in 18 (95%) of 19 EOC patients;
grade 3 and 4 HFSR were not observed. No fistulae or perforations
occurred in the six EOC patients on intermittent sorafenib. Clinical
Table 3 Grade 2–5 toxicity by maximum grade per patient (N¼17)
a
DL 4, 5A, 5B
(n¼17)
Ovarian cancer
(n¼19, all DLs)
Maximum
toxicity grade
(no. of patients)
Maximum
toxicity grade
(no. of patients)
G2 G3 G4 G2 G3 G4
Diarrhoea 2 2 0 2 1 0
Fatigue 2 1 0 4 2 0
Fistula 1 0 0 2 0 0
Mucositis
a 320000
Skin rashes
HFSR 8
a 00 1 7 00
Other
b 200000
Hypertension 7 3 0 9 6 0
Perforation 0 1 0 0 0 0
Proteinuria 2 0 0 1 1 0
Thrombocytopaenia 0 0 0 0 1 0
Thrombosis 0 2 0 1 0 1
Transaminitis 2 2 0 3 1 0
DLs¼dose levels; HFSR¼hand–foot skin reaction.
aOne patient had mouth,
tongue, throat. and anal mucositis.
bEar and perirectal desquamation and rashes.
Table 4 Toxicity comparison of intermittent vs continuous dose
schedule
DL 4, 5A, 5B (N¼17) DL 1, 2 (N¼39)
Toxicity grade G2–4 No. of patients (%)
Diarrhoea 4/17 (24) 7/39 (20)
Fatigue 3/17 (18) 15/39 (38)
Fistula 1/17 (6) 2/39 (5)
Mucositis
a 5/17 (29) NA
Skin rashes
HFSR
b 8
a/17 (47) 23/39 (59)
Other
c 2
Hypertension 10/17 (59) 26/39 (67)
Perforation 1/17 (6) 1/39 (3)
Proteinuria 2/17 (12) 6/39 (15)
Thrombocytopaenia 0/17 (0) 2/39 (5)
Thrombosis 2/17 (12) 3/39 (8)
Transaminitis 4/17 (24) 13/39 (33)
DLs¼dose levels; HFSR¼hand–foot skin reaction; NA¼not applicable.
aOne
patient had mouth, tongue, throat, and anal mucositis.
bAlthough the numbers are
small, when the difference in HFSR is compared between those receiving intermittent
and continuous sorafenib schedules using the w
2-test, P¼0.08.
cEar and perirectal
desquamation and rashes (separate patient with HFSR).
Bevacizumab and intermittent sorafenib activity and toxicity
J-M Lee et al
497
British Journal of Cancer (2010) 102(3), 495–499 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sbenefit was observed in 15 of 19 (79%) assessable patients
(median, 8 months; range 4–37). These patients were heavily
pretreated with cytotoxic agents, with a median of five previous
treatments, and all had documented progressive disease before
study. Confirmed PR was seen in 8 (42%) of 19 patients with EOC,
including all DLs (20, 22, 37, 26, 13, 4, 26, and 8 months). Seven
additional patients had disease stabilisation for at least 4 months.
Our results show a promising response rate in heavily pretreated
patients with platinum-resistant EOC with an acceptable tolerance
of the refined sorafenib dose schedule.
DISCUSSION
Inhibition of angiogenesis has emerged as an important ther-
apeutic strategy. We reported the first study of a combination
therapy with two anti-VEGF-targeted agents applied in series. Our
preliminary results showed an unexpectedly high response rate
(46%) in patients with relapsed EOC (Sieczkiewicz et al, 2002; Jain,
2005). In the original dose escalation study, sorafenib at 200mg
b.i.d. with bevacizumab 5mgkg
 1 every 2 weeks was not tolerable
long term and a substantial number of patients (62%) experienced
fatigue, hand–foot syndrome, hypertension, proteinuria, and
thrombocytopaenia. Although none of these side effects represents
a new toxicity signal for these agents, the incidence of adverse
events was greater than what would be expected through the use of
each agent alone at standard doses. Therefore, we pursued this
regimen with intermittent schedule using sorafenib 5 days of 7
each week. We observed a similar pattern of adverse events and a
continued need to decrease the dose of sorafenib to 200mg once
daily, although not in as many patients as with the continuous
daily dose schedule. Moreover, the patients did not lose clinical
benefit after sorafenib reduction when given with bevacizumab.
Eight of 10 patients who remained on the study for 4 months or
more required sorafenib dose reduction (to 200mg (n¼6) or
400mg (n¼2) once daily, days 1–5 a week). Dose modification of
sorafenib occurred on all three DLs. Hand–foot skin reaction
was a common cause of dose reduction with both schedules.
We also examined the potential value of this regimen in a group of
19 treated EOC patients and demonstrated value independent
of the schedule and dose administered supporting the ongoing
phase II trial.
A goal of the schedule of the components in this trial was to
identify the optimal dose combination and the DLT. The
pharmacodynamic interactions demonstrated that the tolerable
dose of bevacizumab used is half or less of the recommended dose
in other solid tumour studies (Azad et al, 2008b). We were unable
to escalate beyond 5mgkg
 1 every 2 weeks because of proteinuria
(n¼2), thrombocytopaenia (n¼1), and hypertension in DL 5A
(n¼2). Dose-limiting hypertension was less common with the
intermittent sorafenib schedule. Thus, the intermittent sorafenib
dose schedule in combination with bevacizumab is recommended
for phase II application and is the dose and schedule of our
ongoing phase II study in EOC.
Several phase I or II studies have investigated the combination
of bevacizumab with other targeted agents. In a Phase I study of
the combination of bevacizumab and sunitinib in 25 patients with
metastatic renal cell cancer (mRCC), Feldman et al (2009) reported
that the MTD was sunitinib 50mg and bevacizumab 10mgkg
 1
every 2 weeks. Although a high objective response rate (52%) was
observed, 48% discontinued study because of grade 3 or 4
hypertension, haematologic, or vascular toxicities. Another trial
of this combination for all solid tumours is currently ongoing
and has not observed the same high rates of adverse events.
Hainsworth et al (2005) reported a 25% response rate and
1-year PFS of 43% in patients with mRCC treated with full-dose
erlotinib and bevacizumab. Everolimus (10mg daily), in combina-
tion with bevacizumab 10mgkg
 1 every 2 weeks, has been
investigated in a phase II study in mRCC previously treated with
sorafenib and/or sunitinib. Grade 3–4 proteinuria occurred in 19%
with grade 1–2 toxicities of skin rash/pruritus (55%), mucositis/
stomatitis (49%), and hypertension (25%). Objective response
(21%) and SD (69%) were observed in 42 evaluable patients.
Sosman and Puzanov (2009) evaluated the combination of
sorafenib and bevacizumab in a phase I/II trial in mRCC yielding
PRs in 4 of 14 patients. Hand–foot skin reaction, hypertension,
and stomatitis were dose limiting. These phase I/II studies have
provided preliminary evidence of potential clinical benefit of
this combination of STIs with bevacizumab. The patterns of DLT
vary depending upon the STI in the combination, in some cases,
toxicity precluded further application of the combination.
Optimising the management of adverse effects and better selection
of patients for treatment with these combinations may improve
the benefits.
The intermittent sorafenib dose schedule was based on the
hypothesis that the 2-day drug holiday would be associated
with a rapid reduction in symptoms. This was based on our
observations identifying a rapid attenuation of severity of HFSR
and constitutional symptoms; the pharmacokinetic profile of
sorafenib is known to hit a stable steady state by 1 week. This
schedule resulted in the same extent of clinical benefit as in the
original DLs with continuous daily dosing of sorafenib (59%).
Clinical benefit was observed in 59% of patients on our trial.
Our patients were heavily pretreated, and all had documented
progressive disease before study. Our results show a promising
response rate in heavily pretreated patients with platinum-
resistant EOC. Nine of 19 (47%) patients with EOC attained
PR, and six patients had disease stabilisation for at least 4 months.
Overall, clinical benefit was observed in 15 (79%) of 19 patients
(median, 8 months; range, 4–37 months). These results compare
favourably with the phase II results of single-agent bevacizumab
(15mgkg
 1 every 3 weeks) in patients with minimally pretreated
relapsed EOC, two or fewer earlier regimens, that yielded a 21%
response rate, with 40% of patients progression-free at 6 months
and no perforations (Burger et al, 2007). Cannistra et al (2007)
reported a phase II trial of bevacizumab 15mgkg
 1 every 3 weeks
in platinum-resistant EOC patients with three or fewer
earlier regimens. In this study, response rate was 16%, median
PFS 4.4 months and 11% of those enrolled experienced
perforations. Although direct comparison of our trial is not
Table 5 Clinical outcome
Dose level n Best response Time on study (months)
18
a PR (5) 22, 26, 13, 37, 20
SD (3) 6, 5, 4
23
a PR (1) 4
SD (2) 5, 4
42
a PR (1) 26
SD (1) 5
1(uterine) SD (1) 4
1(br) SD (1) 4
1(bcc) SD (1) 4
5a 1
a SD (1) 8
1 SD (1) 9
5b 1
a PR (1) 8
2 (cx) SD (2) 5, 7
All ovarian cancer
(N¼19; all DLs)
Intermittent sorafenib
(DL 4, 5A, 5B; N¼17)
PR 8/19¼42% PR 2/17 (12%)
PR or SDX 4 cycles; 15/19¼79% PR or SDX 4 cycles; 10/17 (59%)
cx¼cervical cancer; bcc¼basal cell cancer; br¼breast cancer; PR¼partial
response; SD¼stable disease;
aovarian cancer. SD other (1 each): melanoma,
sarcoma, urothelial cancer.
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therapy among EOC patients, and our regimen had no perforations
in 19 patients. On the basis of these promising phase I data, we are
now conducting a phase II study of bevacizumab with this
intermittent schedule of sorafenib in EOC.
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